Ultragenyx Pharmaceutical Inc.

NasdaqGS:RARE

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

Location

United States

Market Cap

USD 3.51 B

Share Price

USD 36.52

Avg Daily Volume

934,614

Change (1 day)

-1.62%

Change (1 year)

-11.83%

Change (YTD)

-13.19%

Ultragenyx Pharmaceutical Inc. Revenue Year-on-Year (YoY) growth for the Trailing 12 Months (TTM) ending March 31, 2025: 33.46%

Ultragenyx Pharmaceutical Inc. Revenue Year-on-Year (YoY) growth is 33.46% for the Trailing 12 Months (TTM) ending March 31, 2025. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period. Year-on-Year (YoY) growth is the change in a financial metric compared to the same period in the previous year, expressed as a percentage.

Ultragenyx Pharmaceutical Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 442.59 M, a 15.29% change year over year.
Ultragenyx Pharmaceutical Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 383.89 M, a 15.65% change year over year.
Ultragenyx Pharmaceutical Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 331.95 M, a -0.65% change year over year.
Ultragenyx Pharmaceutical Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 334.12 M, a 174.20% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue Year-on-Year (YoY) growth	Gross Profit	Operating Income	EBIT

NasdaqGS: RARE

Ultragenyx Pharmaceutical Inc.

CEO	Dr. Emil D. Kakkis M.D., Ph.D.
IPO Date	Jan. 31, 2014
Location	United States
Headquarters	60 Leveroni Court
Employees	1,294
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials

Description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.